Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells

Gao,Yanyan; Li,Wei; Liu,Xiaobo; Gao,Fusheng; Zhao,Xiaohua

doi:10.3892/mmr.2014.2936

Reversing effect and mechanism of soluble resistance-related calcium-binding protein on multidrug resistance in human lung cancer A549/DDP cells

Authors:
- Yanyan Gao
- Wei Li
- Xiaobo Liu
- Fusheng Gao
- Xiaohua Zhao
View Affiliations

Affiliations: Department of Internal Medicine, Weifang Medical University, Weifang, Shandong 261053, P.R. China, Department of Chest Surgery, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China, Department of Chest Surgery, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261041, P.R. China, Department of Respiratory Medicine, The Affiliated Hospital of Weifang Medical University, Weifang, Shandong 261041, P.R. China
Published online on: November 13, 2014 https://doi.org/10.3892/mmr.2014.2936
Pages: 2118-2124

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is the primary malignancy of the lung and is the leading cause of cancer‑associated mortality in China. Multidrug resistance (MDR) is an essential aspect of lung cancer treatment failure and a popular topic of investigation in tumor studies. Previous studies have demonstrated that soluble resistance‑related calcium‑binding protein (Sorcin) is involved in the MDR of various types of human tumor, and that silencing Sorcin was able to reverse the MDR of several types of cultured human cancer cells. However, the effect and potential mechanism underlying the ability of Sorcin to reverse MDR in human lung cancer remains to be fully elucidated. The present study examined the role of Sorcin in the reversal of MDR in human lung cancer A549/DDP cells. The effects included increased drug sensitivity to cisplatin, apoptotic rate, cell cycle arrest in the G2/M phase and intracellular accumulation of rhodamine‑123, and decreased expression of multidrug resistance gene 1, lung resistance protein, multidrug resistance‑associated protein, glutathione S‑transferase π, ATP‑binding cassette transporter A2 (ABCA2), ABCA5, B‑cell lymphoma 2 and P‑glycoprotein, and the depletion of glutathione in Sorcin‑silenced A549/DDP cells. The present study also revealed that there was a downregulation of p‑Akt and phosphorylated extracellular signal‑regulated kinase (p‑ERK), and a decreased transcriptional activation of nuclear factor κB, signal transducer and activator of transcription (STAT)3, STAT5 and nuclear factor of activated T‑cells following silencing of Sorcin. The results indicated that Sorcin may be used as a potential therapeutic target for MDR through inhibiting the Akt and ERK pathways in human lung cancer.

View Figures

View References

1	Sereno M, Rodríguez-Esteban I, Gómez-Raposo C, et al: Lung cancer and peritoneal carcinomatosis. Oncol Lett. 6:705–708. 2013.PubMed/NCBI
2	Chung AS, Wu X, Zhuang G, et al: An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med. 19:1114–1123. 2013. View Article : Google Scholar : PubMed/NCBI
3	Sadava D and Kane SE: Silibinin reverses drug resistance in human small-cell lung carcinoma cells. Cancer Lett. 339:102–106. 2013. View Article : Google Scholar : PubMed/NCBI
4	Li X, Wang J, Liu J, et al: Engagement of soluble resistance-related calcium binding protein (sorcin) with foot-and-mouth disease virus (FMDV) VP1 inhibits type I interferon response in cells. Vet Microbiol. 166:35–46. 2013. View Article : Google Scholar : PubMed/NCBI
5	Hu Y, Li S, Yang M, et al: Sorcin silencing inhibits epithelial-to-mesenchymal transition and suppresses breast cancer metastasis in vivo. Breast Cancer Res Treat. 143:287–299. 2014. View Article : Google Scholar
6	Li GY, Liu JZ, Zhang B, et al: Tegillarca granosa extract Haishengsu (HSS) suppresses expression of mdr1, BCR/ABL and sorcin in drug-resistant K562/ADM tumors in mice. Adv Med Sci. 58:112–117. 2013. View Article : Google Scholar : PubMed/NCBI
7	Maddalena F, Laudiero G, Piscazzi A, et al: Sorcin induces a drug-resistant phenotype in human colorectal cancer by modulating Ca(²⁺) homeostasis. Cancer Res. 71:7659–7669. 2011. View Article : Google Scholar : PubMed/NCBI
8	Landriscina M, Laudiero G, Maddalena F, et al: Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents. Cancer Res. 70:6577–6586. 2010. View Article : Google Scholar : PubMed/NCBI
9	Hu Y, Cheng X, Li S, et al: Inhibition of sorcin reverses multidrug resistance of K562/A02 cells and MCF-7/A02 cells via regulating apoptosis-related proteins. Cancer Chemother Pharmacol. 72:789–798. 2013. View Article : Google Scholar : PubMed/NCBI
10	Qu Y, Yang Y, Liu B, et al: Comparative proteomic profiling identified sorcin being associated with gemcitabine resistance in non-small cell lung cancer. Med Oncol. 27:1303–1308. 2010. View Article : Google Scholar
11	Kawakami M, Nakamura T, Okamura N, et al: Knock-down of sorcin induces up-regulation of MDR1 in HeLa cells. Biol Pharm Bull. 30:1065–1073. 2007. View Article : Google Scholar : PubMed/NCBI
12	Akazawa Y, Kawaguchi H, Funahashi M, et al: Effect of interferons on P-glycoprotein-mediated rhodamine-123 efflux in cultured rat hepatocytes. J Pharm Sci. 91:2110–2115. 2002. View Article : Google Scholar : PubMed/NCBI
13	Toner AP, McLaughlin F, Giles FJ, et al: The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance. Br J Cancer. 109:2131–2141. 2013. View Article : Google Scholar : PubMed/NCBI
14	Tajitsu Y, Ikeda R, Nishizawa Y, et al: Molecular basis for the expression of major vault protein induced by hyperosmotic stress in SW620 human colon cancer cells. Int J Mol Med. 32:703–708. 2013.PubMed/NCBI
15	Keppler D: Multidrug resistance proteins (MRPs, ABCCs): importance for pathophysiology and drug therapy. Handb Exp Pharmacol. 201:299–323. 2011. View Article : Google Scholar
16	Zheng BB, Zhang P, Jia WW, Yu LG and Guo XL: Sorcin, a potential therapeutic target for reversing multidrug resistance in cancer. J Physiol Biochem. 68:281–287. 2012. View Article : Google Scholar : PubMed/NCBI
17	Boonstra R, Timmer-Bosscha H, van Echten-Arends J, et al: Mitoxantrone resistance in a small cell lung cancer cell line is associated with ABCA2 upregulation. Br J Cancer. 90:2411–2417. 2004.PubMed/NCBI
18	Noguchi K, Katayama K and Sugimoto Y: Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmgenomics Pers Med. 7:53–64. 2014.PubMed/NCBI
19	Huang L, Lu Q, Han Y, Li Z, Zhang Z and Li X: ABCG2/V-ATPase was associated with the drug resistance and tumor metastasis of esophageal squamous cancer cells. Diagn Pathol. 7:1802012. View Article : Google Scholar : PubMed/NCBI
20	Cuestas ML, Sosnik A and Mathet VL: Poloxamines display a multiple inhibitory activity of ATP-binding cassette (ABC) transporters in cancer cell lines. Mol Pharm. 8:1152–1164. 2011. View Article : Google Scholar : PubMed/NCBI
21	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI
22	Liu Y, Liu JH, Chai K, Tashiro S, Onodera S and Ikejima T: Inhibition of c-Met promoted apoptosis, autophagy and loss of the mitochondrial transmembrane potential in oridonin-induced A549 lung cancer cells. J Pharm Pharmacol. 65:1622–1642. 2013. View Article : Google Scholar : PubMed/NCBI
23	Kohsaka S, Takahashi K, Wang L, et al: Inhibition of GSH synthesis potentiates temozolomide-induced bystander effect in glioblastoma. Cancer Lett. 331:68–75. 2013. View Article : Google Scholar
24	Tang SC, Wu CH, Lai CH, et al: Glutathione S-transferase mu2 suppresses cancer cell metastasis in non-small cell lung cancer. Mol Cancer Res. 11:518–529. 2013. View Article : Google Scholar : PubMed/NCBI
25	Paolo M, Assunta S, Antonio R, et al: Selumetinib in advanced non small cell lung cancer (NSCLC) harbouring KRAS mutation: endless clinical challenge to KRAS-mutant NSCLC. Rev Recent Clin Trials. 8:93–100. 2013. View Article : Google Scholar : PubMed/NCBI
26	Dauphin M, Barbe C, Lemaire S, et al: Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas. Lung Cancer. 81:117–122. 2013. View Article : Google Scholar : PubMed/NCBI
27	Zhao G, Zhang JG, Shi Y, et al: MiR-130b is a prognostic marker and inhibits cell proliferation and invasion in pancreatic cancer through targeting STAT3. PLoS One. 8:e738032013. View Article : Google Scholar : PubMed/NCBI
28	Jans R, Mottram L, Johnson DL, et al: Lysophosphatidic acid promotes cell migration through STIM1- and Orai1-mediated Ca²⁺(i) mobilization and NFAT2 activation. J Invest Dermatol. 133:793–802. 2013. View Article : Google Scholar :